Navigation Links
News brief: Long-term testicular cancer survivors at high risk for neurological side effects
Date:11/25/2009

Long-term survivors of testicular cancer who were treated with cisplatin-based chemotherapy had more severe side effects, including neurological side effects and Raynaud-like phenomena, than men who were not treated with chemotherapy, according to a new study published online November 25 in the Journal of the National Cancer Institute.

Marianne Brydy, M.D., of the Department of Oncology, Haukeland University Hospital, in Bergen, Norway, and colleagues conducted a cross-sectional study to assess the prevalence of these known side effects among long-term testicular cancer survivors in Norway according to the treatment they had received. Side effects include sensory neuropathy, tinnitus, hearing impairment, and Raynaud-like phenomena (discoloration of the hands or feet on exposure to cold).

Researchers invited 1,814 men who were treated for unilateral testicular cancer during 1980-1994 to participate in a national multicenter follow-up survey conducted during 1998-2002. A total of 1,409 participants, who were allocated to three groups based on cisplatin administration, were assessable in this study.

The researchers found that at 4-21 years after the initiation of treatment for testicular cancer, men who had received any chemotherapy had statistically significantly higher odds for increasing severity of all assessed symptoms compared with men not treated with chemotherapy. Treated men also had more hearing impairment, as measured by audiometry, particularly those who had received dose-intensive chemotherapy.

"A major aim in the treatment of testicular cancer is to minimize toxic effects without compromising the high cure rate," the authors write. "Our data favor the use of chemotherapy regimens that contain 20 mg/m2 cisplatin per day to limit ototoxicity."


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. In brief: New prognostic indicator for patients with IPF
2. JNCI news brief: Improving the biomarker pipeline for early cancer detection
3. JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
4. JNCI news brief: Breast cancer hormone receptor status and risk of a second primary tumor
5. JNCI news brief: Antibody linked to chemotherapy drug inhibits ovarian cancer in lab
6. JNCI news brief: High serum insulin levels and risk of prostate cancer
7. JNCI news brief: Surgeon training found effective in breast cancer sentinel lymph node trial
8. JNCI news brief: Melanosome dynamics and sensitivity of melanoma cells to chemotherapy
9. JNCI news brief: STD confirmed to be associated with increased risk of prostate cancer
10. News brief: Effects of aspirin and folic acid on inflammation markers for colorectal adenomas
11. News brief: Estrogen receptor-alpha, breast cancer patients and tamoxifen response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... Indianapolis, IN (PRWEB) , ... April 25, 2017 ... ... Washington, D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration ... Life Financial will provide insight into what changes are most likely to make ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would like ... in a fraction of the time as traditional braces – Wilckodontics®. Dr. Victoria ... now offers this revolutionary treatment with or without a referral. , Wilckodontics ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in ... to dispensaries and head shops –can’t help but be heartened by the industry’s current ... cannabis odor aptly described as “skunk smell.” At last they can simply, safely ...
(Date:4/25/2017)... ... 25, 2017 , ... There is no better place in South Florida to ... in the May issue of Consumer Reports focused on heart health. , The ... during and after coronary bypass and aortic valve replacement procedures. , Consumer Reports ...
(Date:4/24/2017)... ORLANDO, FLORIDA (PRWEB) , ... April 24, 2017 ... ... of telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth ... compliment LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
Breaking Medicine Technology: